Foucher Arlette
Unité du sommeil, service d'explorations fonctionnelles, hôpital Ambroise-Paré, 9, avenue Charles-de-Gaulle, 92100 Boulogne, France.
Nephrol Ther. 2007 Dec;3(7):463-73. doi: 10.1016/j.nephro.2007.05.006. Epub 2007 Jul 31.
A growing body of epidemiologic, experimental, and therapeutic data supports an association between sleep disordered breathing and cardiovascular morbidity and mortality. Pathophysiologic mechanisms including sympathetic activation, oxidative stress, systemic inflammation, hyperleptinemia, insulin resistance, lipidic peroxydation, may influence the development and progression of hypertension, ischemic cardiopathy, cardiac rythm disturbances, cardiac failure, renal failure and stroke. Treatment of apneas is associated with a decrease in new cardiovascular events. These results support the importance of recognising, treating, and if possible preventing OSA.
越来越多的流行病学、实验和治疗数据支持睡眠呼吸紊乱与心血管疾病的发病率和死亡率之间存在关联。包括交感神经激活、氧化应激、全身炎症、高瘦素血症、胰岛素抵抗、脂质过氧化在内的病理生理机制，可能会影响高血压、缺血性心脏病、心律失常、心力衰竭、肾衰竭和中风的发生和发展。呼吸暂停的治疗与新发心血管事件的减少有关。这些结果支持了认识、治疗以及尽可能预防阻塞性睡眠呼吸暂停的重要性。
